<DOC>
	<DOCNO>NCT02924571</DOCNO>
	<brief_summary>The aim investigation compare use bone marrow aspirate concentrate ( BMAC ) allograft versus recombinant human bone morphogenetic protein-2 ( BMP ) subject undergoing elective thoracolumbar spinal fusion interbody support . The investigator look safety efficacy two different surgical method assess surgery outcomes participant ' quality life .</brief_summary>
	<brief_title>BMAC &amp; Allograft vs BMP-2</brief_title>
	<detailed_description>Currently , many available orthopaedic graft adjunct advantage disadvantage . For example , although effective , BMPs expensive risk side effect . The use BMAC may good alternative use BMPs , may side effect . Subjects schedule elective spinal fusion enrol study assign receive either BMP BMAC . Subjects ask complete questionnaire relate quality life , use pain killer , overall health , well standard radiographic study examine spine pre- post-surgically . Subjects attend 7 visit , happen time standard care visit would normally attend condition . Subjects follow study 2 year total .</detailed_description>
	<criteria>Must 18 year old old Scheduled elective posterior anterior posterior spinal fusion thoracolumbar spine without anterior interbody support Failed least 6 week conservative care No contraindication BMAC ( per manufacturer ) Signed consent form Exclusion criterion : Prior lumbar fusion surgery operative level ( prior discectomy and/or laminectomy allow ) Incompetent miss anterior arch affect level ( e.g . laminectomy , par defect ) Currently require laminectomy level surgery Facet joint implant level absent fracture Posttraumatic vertebral body compromise acute fracture implant level Body mass Index ( BMI ) &gt; 40 Known allergy titanium Paget 's disease , osteomalacia , metabolic bone disease Use medication drug know potentially interfere bone/soft tissue healing ( e.g . chronic systemic steroid ) Unlikely comply followup evaluation schedule Active malignancy define history invasive malignancy , except subject receive treatment display clinical sign symptom least five year Pregnant plan become pregnant length study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>